LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway

Leukemia

Volumn 25, Issue 4, 2011, Pages 575-578

  Hasegawa, H ^a   Yamada, Y ^a   Tsukasaki, K ^a   Mori, N ^b   Tsuruda, K ^a   Sasaki, D ^a   Usui, T ^a   Osaka, A ^a   Atogami, S ^a   Ishikawa, C ^b   MacHijima, Y ^b   Sawada, S ^b   Hayashi, T ^c   Miyazaki, Y ^a   Kamihira, S ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

adult T cell leukemia; apoptosis; caspase 2; LBH589; RAIDD

Indexed keywords

BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; CASPASE 2; CASPASE 9; CHEMOKINE RECEPTOR CCR4; CRADD PROTEIN; DEATH RECEPTOR; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 2 RECEPTOR; PANOBINOSTAT; PROTEIN HBZ SI; PROTEIN KINASE B; PROTEIN P53; PROTEIN PIDD; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DNA MICROARRAY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T CELL LEUKEMIA;

EID: 79954429367     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.315     Document Type: Article

References (66)

1. Baylin SB, Ohm JE. Epigenetic gene silencing in cancerFa mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 2: 107-116. (Pubitemid 43361543)
2. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 9: 769-984.
3. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 1: 38-51. (Pubitemid 43054973)
4. Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 37: 5541-5552. (Pubitemid 47255934)
5. Peart MJ, Tainton KM, Ruefli AA, Dear AE, Sedelies KA, O'Reilly LA et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460-4471. (Pubitemid 36951018)
6. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, Brancolini C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 2003; 14: 12579-12589. (Pubitemid 36800248)
7. Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G et al. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003; 101: 4055-4062. (Pubitemid 36857886)
8. Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N et al. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006; 66: 5781-5789. (Pubitemid 43927132)
9. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-4811. (Pubitemid 44187627)
10. Bao Q, Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 2007; 14: 56-65. (Pubitemid 44911894)
11. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 2003; 63: 5126-5135. (Pubitemid 37022654)
12. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005; 280: 26729-26734. (Pubitemid 41040705)
13. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV et al. HDAC6 regulates Hsp90 acetylation and chaperonedependent activation of glucocorticoid receptor. Mol Cell 2005; 18: 601-607. (Pubitemid 40726236)
14. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005; 105: 1768-1776. (Pubitemid 40223701)
15. Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Boyapalle S et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006; 108: 645-652. (Pubitemid 44061366)
16. Yamada Y, Tomonaga M. The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma 2003; 44: 611-618. (Pubitemid 36304818)
17. Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 2005; 24: 5931-5937. (Pubitemid 43086111)
18. Marriott SJ, Semmes OJ. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 2005; 24: 5986-5995. (Pubitemid 43086116)
19. Gaudray G, Gachon F, Basbous J, Biard-Piechaczyk M, Devaux C, Mesnard JM. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002; 76: 12813-12822. (Pubitemid 35386965)
20. Arnold J, Yamamoto B, Li M, Phipps AJ, Younis I, Lairmore MD et al. Enhancement of infectivity and persistence in vivo by HBZ, a natural antisense coded protein of HTLV-1. Blood 2006; 107: 3976-3982. (Pubitemid 43726804)
21. Cavanagh MH, Landry S, Audet B, Arpin-Andre C, Hivin P, Pare ME et al. HTLV-I antisense transcripts initiating in the 30LTR are alternatively spliced and polyadenylated. Retrovirology 2006; 3: 15.
22. Murata K, Hayashibara T, Sugahara K, Uemura A, Yamaguchi T, Harasawa H et al. A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization. J Virol 2006; 80: 2495-2505. (Pubitemid 43271555)
23. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci USA 2006; 103: 720-725. (Pubitemid 43153092)
24. Mesnard JM, Barbeau B, Devaux C. HBZ, a new important player in the mystery of adult T-cell leukemia. Blood 2006; 108: 3979-3982. (Pubitemid 44913265)
25. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001; 113: 375-382. (Pubitemid 32523141)
26. Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 2007; 25: 5458-5464. (Pubitemid 350232223)
27. Maeda T, Yamada Y, Moriuchi R, Sugahara K, Tsuruda K, Joh T et al. Fas gene mutation in the progression of adult T cell leukemia. J Exp Med 1999; 189: 1063-1071. (Pubitemid 29169823)
28. Hasegawa H, Yamada Y, Harasawa H, Tsuji T, Murata K, Sugahara K et al. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br J Haematol 2005; 128: 253-265.
29. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982; 79: 2031-2035. (Pubitemid 12088563)
30. Posner LE, Robert-Guroff M, Kalyanaraman VS, Poiesz BJ, Ruscetti FW, Fossieck B et al. Natural antibodies to the human T cell lymphoma virus in patients with cutaneous T cell lymphomas. J Exp Med 1981; 154: 333-346. (Pubitemid 11044166)
31. Hasegawa H, Yamada Y, Iha H, Tsukasaki K, Nagai K, Atogami S et al. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 2009; 23: 2090-2101.
32. Hasegawa H, Yamada Y, Komiyama K, Hayashi M, Ishibashi M, Sunazuka T et al. A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosisinducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin J2 production. Blood 2007; 110: 1664-1674. (Pubitemid 47443985)
33. Usui T, Yanagihara K, Tsukasaki K, Murata K, Hasegawa H, Yamada Y et al. Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells. Retrovirology 2008; 5: 34.
34. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 1999; 96: 2110-2115. (Pubitemid 29117876)
35. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R et al. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 2007; 13: 4882-4890. (Pubitemid 47294796)
36. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321. (Pubitemid 28524494)
37. Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002; 99: 1505-1511. (Pubitemid 34533017)
38. Mori N, Fujii M, Ikeda S, Yamada Y, Tomonaga M, Ballard DW et al. Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood 1999; 93: 2360-2368. (Pubitemid 29153640)
39. Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 4: 270-280. (Pubitemid 46480972)
40. Mori N, Matsuda T, Tadano M, Kinjo T, Yamada Y, Tsukasaki K et al. Apoptosis induced by the histone deacetylase inhibitor FR901228 in human T-cell leukemia virus type 1-infected T-cell lines and primary adult T-cell leukemia cells. J Virol 2004; 78: 4582-4590. (Pubitemid 38501079)
41. Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287-296. (Pubitemid 351215535)
42. Duan H, Dixit VM. RAIDD is a new 'death' adaptor molecule. Nature 1997; 385: 86-89. (Pubitemid 27024560)
43. Robertson JD, Enoksson M, Suomela M, Zhivotovsky B, Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 2002; 277: 29803-29809.
44. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002; 277: 13430-13437. (Pubitemid 34967937)
45. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843-846. (Pubitemid 38620177)
46. Tinel A, Janssens S, Lippens S, Cuenin S, Logette E, Jaccard B et al. Autoproteolysis of PIDD marks the bifurcation between pro-death caspase-2 and pro-survival NF-kappaB pathway. EMBO J 2007; 26: 197-208. (Pubitemid 46094711)
47. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2003; 1: 30-37.
48. Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008; 3: 413-432. (Pubitemid 351836289)
49. Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500-4510.
50. Ahmad M, Srinivasula SM, Wang L, Talanian RV, Litwack G, Fernandes-Alnemri T et al. CRADD, a novel human apoptotic adaptor molecule for caspase-2, and FasL/tumor necrosis factor receptor-interacting protein RIP. Cancer Res 1997; 57: 615-619. (Pubitemid 27085642)
51. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002; 297: 1352-1354. (Pubitemid 34913174)
52. Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 2005; 331: 859-867. (Pubitemid 40615517)
53. Mhaidat NM, Wang Y, Kiejda KA, Zhang XD, Hersey P. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol Cancer Ther 2007; 6: 752-761. (Pubitemid 46332476)
54. Robertson JD, Gogvadze V, Kropotov A, Vakifahmetoglu H, Zhivotovsky B, Orrenius S. Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity. EMBO Rep 2004; 6: 643-648. (Pubitemid 39136428)
55. Castedo M, Perfettini JL, Roumier T, Valent A, Raslova H, Yakushijin K et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004; 23: 4362-4370. (Pubitemid 38850415)
56. Manzl C, Krumschnabel G, Bock F, Sohm B, Labi V, Baumgartner F et al. Caspase-2 activation in the absence of PIDDosome formation. J Cell Biol 2009; 185: 291-303.
57. Kim IR, Murakami K, Chen NJ, Saibil SD, Matysiak-Zablocki E, Elford AR et al. DNA damage-and stress-induced apoptosis occurs independently of PIDD. Apoptosis 2009; 14: 1039-1049.
58. Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R et al. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell 2008; 133: 864-877. (Pubitemid 351715394)
59. Pise-Masison CA, Jeong SJ, Brady JN. Human T cell leukemia virus type 1: the role of Tax in leukemogenesis. Arch Immunol Ther Exp (Warsz) 2005; 53: 283-296. (Pubitemid 43186757)
60. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA 2001; 98: 10833-10838. (Pubitemid 32878706)
61. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A et al. Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nature Med 2005; 11: 71-76. (Pubitemid 40215840)
62. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 2000; 97: 10014-10019.
63. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004; 101: 1241-1246. (Pubitemid 38182673)
64. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY et al. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res 2005; 65: 7386-7392. (Pubitemid 41161272)
65. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 11: 1139-1146. (Pubitemid 44430638)
66. Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009; 113: 1287-1293.